Navigation Links
OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Date:6/3/2010

222 and OGX-225 are currently in pre-clinical development.

More information is available at www.OncoGenex.com.

OncoGenex's Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities and the timing of these activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, uncertainties regarding our future operating results, the risk that our product candidates will not obtain the requisite regulatory approvals to commercialize or that the future sales of our product candidates may be less than expected, and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2009. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex Reports First Quarter Financial Results
2. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
3. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
4. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
5. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
6. OncoGenex Reports Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
8. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
9. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
10. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
11. OncoGenex Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... According to a new market research report ... and Joint) Market (By Technology - Stem Cell ... Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic ... Share, Growth, Trends and Forecast, 2013 - 2019" ... was valued at USD 2.6 billion in 2012 ...
(Date:7/28/2014)... 28, 2014 Proove Biosciences , ... be exhibiting data and research conducted through their latest ... Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The ... Hyatt Regency, in Orlando, Florida. , The ... competence of physicians who care for patients suffering specificity ...
(Date:7/28/2014)... Research and Markets has announced the addition ... report to their offering. ... the designing and engineering of completely new biological parts, ... natural biological systems that provide improved and desirable functions. ... genetic engineering because it not only alters existing metabolic ...
(Date:7/28/2014)... -   JOLT , a leading technology accelerator, announced ... growing portfolio of startups. Next-level tech and boundary-pushing innovation ... JOLT accelerator, and Cohort four is no exception, with ... Since its launch in July 2012, JOLT has produced ... Now at 23 investments, JOLT,s portfolio has an overall ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Global Synthetic Biology Market 2014-2018 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3
... RYE, N.Y., Nov. 10 Curemark, LLC, a drug ... autism, was one of 32 biotech companies headed by ... 2009 forum, held recently in Silicon Valley, Madison, Wisconsin, ... from the U.S. and abroad applied to participate. , ...
... ... the prestigious eHealthcare Leadership Award given annually to organizations representing the best web sites ... ... provider of clinical trials information, received its fifth consecutive eHealthcare Leadership Award and seventh ...
... N.J., Nov. 10 Regado Biosciences, a privately held company leading ... Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will ... in Philadelphia, Pennsylvania. Ms. McDonald,s presentation ... Monday, November 16 and will ...
Cached Biology Technology:Curemark Presents at Springboard Enterprises Life Sciences Forum 2CenterWatch Honored a Fifth Consecutive Year for Best Healthcare Content 2Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009 2
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are ... of varying flexibility that can be used as microscale ... proof that "bead-spring" polymers, introduced as theory in the ... as required and should be of interest to materials ... The work led by Rice chemical and biomolecular engineer ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
(Date:7/28/2014)... Amundsen became the first man to reach the South ... later, an international team of scientists led by Joe ... that air pollution from industrial activities arrived long before. ... widely spaced locations around the Antarctic continent, including the ... precise reconstruction to date of lead pollution over the ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... most important fruit trees in the world. Citrus has a ... 4,000 years. Until now, however, the exact genetic origins of ... lemon ( C. limon ), and grapefruit ( C. paradisi ... China has published a study in the Journal of the ...
... at Dana-Farber Cancer Institute have received a $5.6 million ... and the Army Research Office (ARO) to develop transient ... pathogens. The ultimate goal is to develop a ... of receiving it in a laboratory. Wayne A. ...
... , CHAPEL HILL, N.C. Researchers at the University of ... can make brain cells resistant to programmed cell death or ... microRNA-29 or miR-29, has already been shown to be in ... and Huntington,s disease. Thus, the discovery could herald a new ...
Cached Biology News:Genetic origin of cultivated citrus determined 2Dana-Farber receive $5.6 million grant to develop rapid countermeasures to infectious agents 2New molecule could save brain cells from neurodegeneration, stroke 2New molecule could save brain cells from neurodegeneration, stroke 3
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Request Info...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Biology Products: